Synteva 150 mg Tablet is a targeted cancer medicine containing erlotinib. It is used in certain people with non-small cell lung cancer, and in some cases of pancreatic cancer, as part of a treatment plan set by a cancer specialist.
There are 2 brands of Erlotinib listed in Bangladesh. By unit price, Synteva 150 mg is among the cheapest of them.
What is Synteva 150 mg Tablet?
Synteva 150 mg Tablet is a targeted cancer therapy. Its active ingredient is erlotinib, and it comes as a tablet in a 150 mg strength from Synovia Pharma PLC. It belongs to a group of medicines that act on specific targets in cancer cells rather than on the whole body. Doctors prescribe it for particular types of non-small cell lung cancer and, in some situations, pancreatic cancer. It is used only under the guidance of a cancer specialist, who decides whether it suits a person and how the treatment should be given.
Uses of Synteva 150 mg
Synteva 150 mg Tablet is used for first-line treatment of metastatic non-small cell lung cancer in people whose tumours have certain epidermal growth factor receptor mutations. It is also used as maintenance treatment for locally advanced or metastatic non-small cell lung cancer that has not progressed after a set number of cycles of platinum-based chemotherapy. In pancreatic cancer it may be used together with another cancer medicine. A specialist decides whether the medicine is suitable.
How to use Synteva 150 mg
Synteva 150 mg Tablet is taken by mouth. It is usually taken on an empty stomach, at least one hour before or two hours after food. The doctor decides the dose and how long the course continues; do not change the dose yourself. If a dose is missed or vomiting occurs, ask the doctor or pharmacist what to do. Swallow the tablet as directed and keep all follow-up appointments so the treatment can be monitored.
Side effects of Synteva 150 mg
Common side effects of erlotinib include rash, diarrhoea, loss of appetite, tiredness, shortness of breath, cough, nausea and vomiting. Some people develop serious problems, including lung inflammation, kidney problems, liver injury, bowel perforation, serious skin reactions, heart or blood vessel events, eye problems and bleeding, especially with warfarin. Tell your doctor promptly about new or worsening breathing problems, severe diarrhoea, skin changes, eye symptoms or unusual bleeding. The doctor will decide how to manage any side effect.
Safety and precautions
Synteva 150 mg Tablet is not for everyone. Tell your doctor about lung, kidney or liver problems, eye disorders, bowel problems or bleeding risk, and about all other medicines you take, because some medicines change how erlotinib works. It can harm an unborn baby and is not recommended in pregnancy; effective contraception is important during treatment. It is not known whether it passes into breast milk, so breastfeeding decisions should be discussed with the doctor. People with these concerns should ask the doctor before starting treatment.
Frequently asked questions
Who should avoid Synteva 150 mg Tablet or ask the doctor first?
Anyone with lung, liver, kidney, eye or bowel problems, or a bleeding tendency, should tell the doctor before starting. Pregnancy and breastfeeding need special discussion. People taking blood thinners or other medicines that interact with erlotinib should check with the doctor, who will decide whether it is suitable.
What is Synteva 150 mg Tablet used for and what kind of medicine is it?
It is a targeted cancer therapy containing erlotinib. It is used for certain non-small cell lung cancers and, in some cases, pancreatic cancer. It acts on specific targets in cancer cells. A cancer specialist decides whether it is appropriate and how treatment should proceed.
What does the generic name erlotinib mean?
Erlotinib is the generic name of the active ingredient in Synteva 150 mg Tablet. It refers to a targeted cancer medicine that blocks a specific signalling pathway in certain cancer cells. The generic name identifies the medicine itself, while Synteva is the brand name from Synovia Pharma PLC.
Can I take Synteva 150 mg Tablet with other medicines?
Some medicines can change how erlotinib works or raise the risk of side effects, including blood thinners and certain antibiotics or antifungal medicines. Always tell your doctor and pharmacist about every medicine, supplement or herbal product you use, and let them decide what is suitable.
First-line treatment of patients with metastatic Non-Small Cell Lung cancer (NSCLC) whose tumors have Epidermal Growth Factor Receptor (EGFR) exon 19 deletions or exon 21 substitution mutations as detected.
Maintenance treatment of patients with locally advanced or metastatic NSCLC whose ... Read moreFirst-line treatment of patients with metastatic Non-Small Cell Lung cancer (NSCLC) whose tumors have Epidermal Growth Factor Receptor (EGFR) exon 19 deletions or exon 21 substitution mutations as detected.
Maintenance treatment of patients with locally advanced or metastatic NSCLC whose disease has not progressed after four cycles of platinum based first-line chemotherapy.
Treatment of locally advanced or metastatic NSCLC after failure of at least one prior chemotherapy regimen.
First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.
Dosage & Administration
NSCLC: The recommended daily dose of Erlotinib for NSCLC is 150 mg taken on an empty stomach, i.e., at least one hour before or two hours after the ingestion of food. Treatment should continue until disease progression or unacceptable toxicity occurs.
Pancreatic Cancer: The recommended daily dose of Erlotinib for pancreatic cancer is 100 mg taken once daily in combination with gemcitabine. Take Erlotinib on an empty stomach, i.e., at least one hour before or two hours after the ingestion of food. Treatment should continue until disease progression or unacceptable toxicity occurs.
Reduce Erlotinib by 50 mg decrements: If severe reactions occur with concomitant use of strong CYP3A4 inhibitors (such as atazanavir, Clarithromycin, Indinavir, Itraconazole, Ketoconazole, Nefazodone, Nelfinavir, Ritonavir, Saquinavir, Telithromycin, Voriconazole or grapefruit or grapefruit juice] or when using concomitantly with an inhibitor of both CYP3A4 and CYP1A2 (e.g., Ciprofloxacin).
Increase Erlotinib by 50 mg increments as tolerated for: Concomitant use with CYP3A4 inducers, such as rifampin, rifabutin, rifapentine, phenytoin, carbamazepine, phenobarbital, or St. John's Wort. Increase doses by 50 mg increments at 2 week intervals to a maximum of 450 mg. Avoid concomitant use, if possible.
Concurrent cigarette smoking: Increase by 50 mg increments at 2 week intervals to a maximum of 300 mg. Immediately reduce the dose of Erlotinib to the recommended dose (150 mg or 100 mg daily) upon cessation of smoking.
Interaction
Anticoagulants: Interaction with coumarin-derived anticoagulants, including warfarin, leading to increased International Normalized Ratio (INR) and bleeding adverse reactions.
CYP3A4 inhibitors: Erlotinib is metabolized predominantly by CYP3A4. Co-treatment with the potent CYP3A4 inhibitor ketoconazole increased Erlotinib AUC by 67%. When Erlotinib was co-administered with Ciprofloxacin, an inhibitor of both CYP3A4 and CYP1A2, the Erlotinib exposure [AUC] and maximum concentration [Cmax] increased by 39% and 17%, respectively.
CYP3A4 inducers: Pre-treatment with the CYP3A4 inducer Rifampicin for 7-11 days prior to Erlotinib decreased Erlotinib AUC by 58% to 80%. Dose modifications are recommended.
Drugs affecting gastric pH: Co-administration of Erlotinib with omeprazole decreased Erlotinib AUC by 46% and co-administration of Erlotinib with Ranitidine 300 mg decreased Erlotinib AUC by 33%.
Side Effects
The most common adverse reactions (20%) with Erlotinib from a pooled analysis of studies were rash, diarrhea, anorexia, fatigue, dyspnea, cough, nausea, and vomiting. The following serious adverse reactions, which may include fatalities.
Interstitial Lung Disease (ILD)
Renal Failure
Hepatotoxicity with or without Hepatic Impairment
Gastrointestinal Perforation
Bullous and Exfoliative Skin Disorders
Myocardial Infarction/Ischemia
Cerebrovascular Accident
Microangiopathic Hemolytic Anemia with Thrombocytopenia
Ocular Disorders
Hemorrhage in Patients Taking Warfarin
Pregnancy & Lactation
Pregnancy category D. Based on its mechanism of action, Erlotinib can cause fetal harm when administered to a pregnant woman. It is not known whether Erlotinib is present in human milk. Because many drugs are present in human milk and because of the potential for serious adverse reactions in nursing infants from Erlotinib, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Precautions & Warnings
Interstitial Lung Disease (ILD): Occurs in 1.1% of patients. Withhold Erlotinib for acute onset of new or progressive unexplained pulmonary symptoms, such as dyspnea, cough and fever. Discontinue Erlotinib if ILD is diagnosed.
Renal Failure: Monitor renal function and electrolytes, particularly in patients at risk of dehydration. Withhold Erlotinib for severe renal toxicity.
Hepatotoxicity with or without hepatic impairment including hepatic failure and hepatorenal syndrome: Monitor periodic liver testing. Withhold or discontinue Erlotinib for severe or worsening liver tests.
Bullous and exfoliative skin disorders-discontinue Erlotinib.
Myocardial infarction (Ml)/ischemia: The risk of Ml is increased in patients with pancreatic cancer.
Overdose Effects
Single oral doses of Erlotinib up to 1,000 mg in healthy subjects and weekly doses up to 1,600 mg in cancer patients have been tolerated. Repeated twice-daily doses of 200 mg single-agent Erlotinib in healthy subjects were poorly tolerated after only a few days of dosing. Based on the data from these studies, an unacceptable incidence of severe adverse reactions, such as diarrhea, rash, and liver transaminase elevation, may occur above the recommended dose. In case of suspected overdose, Erlotinib should be withheld and symptomatic treatment instituted.
Storage Conditions
Store at a temperature not exceeding 30°C in a dry place. Protect from light and moisture.
Alternative brands of Erlotinib
Other brands with the same generic name, cheapest first.